EUCTR2009-012189-30-GB进行中（未招募）1 期
An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy - N/A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Algeta ASA
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients may be included in the study if they meet all of the following criteria:
- •1. Patient is female, and either post-menopausal (cessation of menses for more than 1 year) or surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy) or in therapy-induced premature menopause with LHRH agonists. If of childbearing potential the result of a urine human chorionic gonadotropin pregnancy test, performed on the same day as and with the result known before study drug administration, must be negative.
- •2. Histological or cytological evidence of primary breast cancer.
- •3. Bone dominant disease (with or without metastases in soft tissue, lymph nodes and/or skin) with at least one non-irradiated bone metastasis on planar bone scintigraphy/SPECT ± CT within previous the 12 weeks.
- •4. Patient has unequivocally progressed on endocrine therapy and further benefit from endocrine therapy is considered unlikely (progression must be documented based on imaging and/or other clinically relevant information).
- •5. Patient has been on bisphosphonate therapy for at least 3 months prior to treatment start and no change to bisphosphonate therapy is expected during the treatment phase of the study, or patient is not being treated with bisphosphonates, and such treatment is not planned to start during the treatment period.
- •6. Latest endocrine therapy stopped at least 2 weeks prior to treatment start.
- •7. ECOG PS 0 – 2.
- •8. Life expectancy =6 months.
- •9. Patient fulfils the following laboratory requirements:
- •White Blood Cell Count (WBC) =3,000/mm3
- •Absolute Neutrophil Count (ANC) =1,500/mm3
- •Platelet (PLT) count =100,000/mm3
- •Haemoglobin (HGB) =9 g/dl
- •Bilirubin =2.0 mg/dl
- •Aspartate aminotransferase (AST) and Alkaline aminotransferase (ALT) =3 times upper institutional limit of the normal range
- •Serum creatinine =2.0 mg/dl 10. Patient must be able and willing to sign an informed consent form indicating that she is aware of the investigational nature of this study in keeping with the policies of the institution, and must have provided written authorisation for use and disclosure of protected health information. 11. Patient must be willing and able to comply with the protocol and agree to return to the hospital for follow-up visits and examination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients must be excluded from participating in this study if they meet any of the following criteria:
- •1. Received an investigational drug within 4 weeks prior to the administration of Alpharadin, or is scheduled to receive one during the treatment period.
- •2. Received chemotherapy, immunotherapy, or external beam radiation therapy within the last 4 weeks prior to administration of study drug, or has not recovered from acute adverse reactions (ARs) as a result of such therapy.
- •3. Is likely to require chemotherapy or immunotherapy within the 16 weeks treatment period.
- •4. Presence of imminent or established spinal cord compression based on clinical findings and/or Magnetic Resonance Imaging (MRI).
- •5. Presence of other currently active (relapse within the last 3 years) malignancy (except non-melanoma skin cancer) that are not breast cancer metastases.
- •6. Presence of unequivocal visceral metastases requiring chemotherapy treatment in the next 6 months, based on Investigator’s judgement. Brain metastases are allowed only if well controlled and if not associated with symptoms. Treatment for brain metastasis should have been completed at least 8 weeks prior to treatment start.
- •7. Patients with any other serious illness or medical condition, such as:
- •Any uncontrolled infection
- •Clinical heart failure severe enough to cause marked limitation of activity, and who is only comfortable at rest; or heart failure more severe than this (New York Heart Association (NYHA) Heart Failure Class III or IV)
- •Crohn’s disease or ulcerative colitis
- •Bone marrow myelodysplasia
- •Unmanageable faecal incontinence
研究者
相似试验
进行中（未招募）
1 期
An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy - N/AEUCTR2009-012189-30-BEAlgeta ASA20
已完成
不适用
An open label, non-randomized phase I/II study of ramucirumab in combination with nab-paclitaxel as second-line therapy in patients with advanced gastric cancergastric cancerJPRN-UMIN000020579Digestive Disease Support Organization (DDSO)68
进行中（未招募）
1 期
Study that tested S64315 plus different standard treatments in patients with breast cancerEUCTR2019-000998-23-ESInstitut de Recherches Internationales Servier
进行中（未招募）
不适用
Open label study with Dasatinib in patients with Chronic Phase Chronic Myeloid Leukemia treated with ImatinibChronic Phase Chronic Myeloid LeukemiaMedDRA version: 14.1Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2011-006181-41-ITBristol-Myers Squibb International Corporation180
进行中（未招募）
1 期
Open label study with Dasatinib in patients with Chronic Phase Chronic Myeloid Leukemia treated with ImatinibChronic Phase Chronic Myeloid LeukemiaMedDRA version: 20.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000013009EUCTR2011-006181-41-BEBristol-Myers Squibb International Corporation258